Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Axis Capital Limited
$35.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jubilant Life Sciences Ltd receives ANDA approval for Spironolactone Tablets


Friday, 25 Apr 2014 04:59am EDT 

Jubilant Life Sciences Ltd:Says it receives Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (US FDA) for Spironolactone Tablets, 25 mg, 50 mg and 100 mg, the generic version of Aldactone (of GD Searle).Says which is used as a diuretic to treat fluid retention (edema) caused by congestive heart failure and cirrhosis of the liver.Expects to launch this product in Q1 FY15.Says it has also received a tentative approval from the USFDA for Memantine Tablets, 5 mg and 10 mg, the generic version of Namenda (of Forest Labs), which is used for treatment of moderate-to-severe Alzheimer's disease.Expect to launch this product post patent expiry in 2015.Total market size for Namenda as per IMS is $ 1.85 bln per annum. 

Company Quote

149.5
-0.15 -0.10%
27 Mar 2015